Recently, the Russell group developed a genetically modified oVSV expressing IFN-β and sodium iodide symporter and examined this oVSV in phase I clinical trials for patients with refractory multiple myeloma, acute myeloid leukemia, or T-cell lymphoma [20]. This evidence concerns the gene SLC5A5 and T-cell non-Hodgkin lymphoma.